<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cdk5 — Cyclin-Dependent Kinase 5</th>
</tr>
<tr> [@shah2022]
<td class="label">Protein Name</td> [@tarricone2001]
<td><strong>Cdk5 (Cyclin-Dependent Kinase 5)</strong></td> [@seo2017]
</tr> [@bhatt2023]
<tr> [@cheung2006]
<td class="label">Gene</td> [@lopes2010]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1020" target="_blank">CDK5</a> (7q36.1)</td> [@tau]
</tr> [@taua]
<tr> [@gskb]
<td class="label">UniProt</td> [@amyloidbeta]
<td><a href="https://www.uniprot.org/uniprot/Q00535" target="_blank">Q00535</a></td> [@alzheimers]
</tr> [@parkinsons]
<tr> [@nflprotein]
<td class="label">PDB Structures</td> [@excitotoxicity]
<td><a href="https://www.rcsb.org/structure/1H4L" target="_blank">1H4L</a>, <a href="https://www.rcsb.org/structure/1UNL" target="_blank">1UNL</a>, <a href="https://www.rcsb.org/structure/3O0G" target="_blank">3O0G</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~33.3 kDa (291 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cytoplasm, nucleus, synapses, growth cones, perinuclear region</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>CMGC kinase group, CDK family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cdk5 — Cyclin-Dependent Kinase 5</th>
</tr>
<tr> [@shah2022]
<td class="label">Protein Name</td> [@tarricone2001]
<td><strong>Cdk5 (Cyclin-Dependent Kinase 5)</strong></td> [@seo2017]
</tr> [@bhatt2023]
<tr> [@cheung2006]
<td class="label">Gene</td> [@lopes2010]
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1020" target="_blank">CDK5</a> (7q36.1)</td> [@tau]
</tr> [@taua]
<tr> [@gskb]
<td class="label">UniProt</td> [@amyloidbeta]
<td><a href="https://www.uniprot.org/uniprot/Q00535" target="_blank">Q00535</a></td> [@alzheimers]
</tr> [@parkinsons]
<tr> [@nflprotein]
<td class="label">PDB Structures</td> [@excitotoxicity]
<td><a href="https://www.rcsb.org/structure/1H4L" target="_blank">1H4L</a>, <a href="https://www.rcsb.org/structure/1UNL" target="_blank">1UNL</a>, <a href="https://www.rcsb.org/structure/3O0G" target="_blank">3O0G</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~33.3 kDa (291 amino acids)</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cytoplasm, nucleus, synapses, growth cones, perinuclear region</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>CMGC kinase group, CDK family</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">300 edges</a></td>
</tr>
</table>
[Cdk5](/proteins/cdk5-protein) — Cyclin Dependent Kinase 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[Cdk5](/genes/cdk5) ([cdk5](/proteins/cdk5) is a proline-directed serine/threonine kinase that, despite its name, is primarily active in postmitotic [neurons](/entities/neurons) rather than in dividing cells. Unlike other CDK family members, [Cdk5](/proteins/cdk5) is not activated by cyclins but instead requires binding to its neuron-specific activators p35 (CDK5R1) or p39 (CDK5R2) for kinase activity ([Tsai et al., 1994](https://doi.org/10.1038/368461a0)). Under physiological conditions, Cdk5 is essential for brain development, neuronal migration, synaptic function, and neuronal survival. However, pathological conversion of p35 to p25 by calpain-mediated cleavage results in sustained Cdk5 hyperactivation, which drives [tau-protein](/proteins/tau) hyperphosphorylation, neuronal death, and neurodegeneration in [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), [als](/diseases/amyotrophic-lateral-sclerosis), and other conditions ([Shah & Bhatt, 2022](https://doi.org/10.1186/s12929-021-00774-y)).
Cdk5 is now recognized as one of the most important kinases in neurodegeneration and a prime therapeutic target. Its dual nature — essential for neuronal health yet destructive when dysregulated — poses both challenges and opportunities for drug development.
Cdk5 is a 291-amino-acid protein (~33.3 kDa) with the canonical bilobal kinase fold:
Unlike other CDKs, Cdk5 does not require T-loop phosphorylation for activation. Instead, binding of p35 or p39 to the PSSALRE helix induces a conformational change that opens the substrate-binding cleft and positions the catalytic residues for phosphotransfer. This unique activation mechanism explains why Cdk5 escapes the cell-cycle regulatory machinery that controls other CDKs ([Tarricone et al., 2001](https://doi.org/10.1016/S1097-2765(01)00350-0)).
p35 is a short-lived protein (half-life ~20 minutes) normally degraded by the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system), keeping Cdk5 activity tightly controlled. Under neurotoxic stress — including [Amyloid-Beta](/proteins/amyloid-beta) exposure, oxidative stress, excitotoxicity, or ischemia — the calcium-activated protease calpain cleaves p35 into p10 (N-terminal, membrane-anchoring fragment) and p25 (C-terminal, Cdk5-binding fragment). p25 has a much longer half-life (~60 minutes), causing prolonged Cdk5 activation. Moreover, p25 lacks the N-terminal myristoylation signal that anchors p35 to membranes, so the Cdk5/p25 complex is mislocalized from the membrane to the cytoplasm and nucleus, where it accesses pathological substrates including [tau-protein](/proteins/tau), leading to neurodegeneration ([Patrick et al., 1999](https://doi.org/10.1038/46547)).
Cdk5 is essential for proper cortical lamination during embryonic development. Cdk5 knockout mice die at birth with severe cortical layering defects due to failed neuronal migration. Cdk5 phosphorylates multiple substrates required for the cytoskeletal reorganization underlying neuronal migration, including:
At mature synapses, Cdk5 modulates both presynaptic and postsynaptic functions:
Physiological Cdk5/p35 activity promotes neuronal survival through:
Cdk5 directly phosphorylates the KSP repeats in [nfl-protein](/proteins/nfl-protein) medium (NEFM) and heavy (NEFH) chain tail domains. This phosphorylation increases neurofilament sidearm extension, regulating inter-filament spacing and thus axonal caliber. Cdk5-mediated neurofilament phosphorylation is a major determinant of axonal diameter and nerve conduction velocity.
Cdk5/p25 hyperactivation is a central pathogenic mechanism in [alzheimers](/diseases/alzheimers-disease):
In [parkinsons](/diseases/parkinsons-disease), Cdk5 contributes to [dopaminergic-neurons-snpc](/cell-types/dopaminergic-neurons-snpc) degeneration through:
In [als](/diseases/amyotrophic-lateral-sclerosis), Cdk5/p25 activity is elevated in spinal cord motor [neurons](/entities/neurons). Cdk5 hyperactivation contributes to:
In [ftd](/diseases/frontotemporal-dementia) [tauopathies](/mechanisms/tauopathies), Cdk5/p25 inhibition attenuates [tau](/proteins/tau) pathology, neuroinflammation, and neuronal loss. Inhibition of the p25/Cdk5 complex in mouse and iPSC models of FTD reduces tau phosphorylation, [neuroinflammation](/mechanisms/neuroinflammation), DNA damage, and cell cycle re-entry ([Seo et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28965760/)).
Cdk5 phosphorylates [huntingtin](/proteins/huntingtin) at Ser434, which may modulate [huntingtin](/proteins/huntingtin) toxicity and aggregate formation in [huntington-pathway](/mechanisms/huntington-pathway).
A 12-amino-acid Cdk5-derived peptide (CIP) that specifically disrupts the Cdk5/p25 complex without affecting Cdk5/p35 activity represents a more targeted approach. This peptide selectively inhibits the pathological Cdk5/p25 interaction while preserving the physiological Cdk5/p35 function, ameliorating neurodegenerative phenotypes in cell and mouse models ([Bhatt et al., 2023](https://doi.org/10.1073/pnas.2217864120)).
Strategies to prevent p35-to-p25 conversion by inhibiting calpain activity or stabilizing p35 are under investigation. Calpain inhibitors reduce p25 generation and tau hyperphosphorylation in AD models.
The study of Cdk5 — Cyclin Dependent Kinase 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving Cdk5 (Cyclin-Dependent Kinase 5) discovered through SciDEX knowledge graph analysis: